Talphera Inc
TLPH1.100USD
-0.010-0.90%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
50.14MMarket Cap
LossP/E TTM
More Details of Talphera Inc Company
Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company’s portfolio consists of nafamostat product candidates and pre-filled syringe product candidates. The Company’s lead product candidate, Niyad, is a lyophilized formulation of nafamostat and is being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit. Niyad is used in adult patients undergoing continuous renal replacement therapy (CRRT). LTX-608 is its nafamostat formulation for direct IV infusion being explored as an investigational product for one or more indications, including antiviral treatment, or treatment of acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), or acute pancreatitis. The Company’s two ready-to-use pre-filled syringe (PFS) product candidates include Fedsyra and phenylephrine.
Talphera Inc Info
Ticker SymbolTLPH
Company nameTalphera Inc
IPO dateFeb 11, 2011
CEOAngotti (Vincent J)
Number of employees13
Security typeOrdinary Share
Fiscal year-endFeb 11
Address1850 Gateway Drive
CitySAN MATEO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94404
Phone16502163500
Websitehttps://talphera.com/
Ticker SymbolTLPH
IPO dateFeb 11, 2011
CEOAngotti (Vincent J)
Company Executives of Talphera Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Shakil Aslam
Dr. Shakil Aslam
Chief Development Officer, Chief Medical Officer
Chief Development Officer, Chief Medical Officer
42.48K
-9.61%
Mr. Adrian Adams
Mr. Adrian Adams
Independent Chairman of the Board
Independent Chairman of the Board
17.61K
+31.98%
Mr. Badri N. Dasu
Mr. Badri N. Dasu
Chief Engineering Officer
Chief Engineering Officer
15.61K
-76.52%
Mr. Mark Allen Wan
Mr. Mark Allen Wan
Independent Director
Independent Director
8.86K
+92.92%
Mr. Abhinav (Abi) Jain
Mr. Abhinav (Abi) Jain
Independent Director
Independent Director
6.73K
+173.17%
Mr. Joseph (Joe) Todisco
Mr. Joseph (Joe) Todisco
Director
Director
6.40K
--
Mr. Raffi M. Asadorian
Mr. Raffi M. Asadorian
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Jill M. Broadfoot
Ms. Jill M. Broadfoot
Independent Director
Independent Director
--
--
Mr. Vincent J. (Vince) Angotti
Mr. Vincent J. (Vince) Angotti
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Marina S. Bozilenko
Ms. Marina S. Bozilenko
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Shakil Aslam
Dr. Shakil Aslam
Chief Development Officer, Chief Medical Officer
Chief Development Officer, Chief Medical Officer
42.48K
-9.61%
Mr. Adrian Adams
Mr. Adrian Adams
Independent Chairman of the Board
Independent Chairman of the Board
17.61K
+31.98%
Mr. Badri N. Dasu
Mr. Badri N. Dasu
Chief Engineering Officer
Chief Engineering Officer
15.61K
-76.52%
Mr. Mark Allen Wan
Mr. Mark Allen Wan
Independent Director
Independent Director
8.86K
+92.92%
Mr. Abhinav (Abi) Jain
Mr. Abhinav (Abi) Jain
Independent Director
Independent Director
6.73K
+173.17%
Mr. Joseph (Joe) Todisco
Mr. Joseph (Joe) Todisco
Director
Director
6.40K
--
Revenue Breakdown
Currency: USDUpdated: Wed, Mar 5
Currency: USDUpdated: Wed, Mar 5
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
By BusinessUSD
Name
Revenue
Proportion
DSUVIA
1.59M
89.67%
DZUVEO
183.00K
10.33%
Zalviso
0.00
0.00%
Non-cash royalty revenue related to Royalty Monetization
0.00
0.00%
Other revenue
0.00
0.00%
Other
0.00
0.00%
Relevant data have not been disclosed by the company yet.
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
DSUVIA
1.59M
89.67%
DZUVEO
183.00K
10.33%
Zalviso
0.00
0.00%
Non-cash royalty revenue related to Royalty Monetization
0.00
0.00%
Other revenue
0.00
0.00%
Other
0.00
0.00%
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
CorMedix Inc
19.50%
Rosalind Advisors, Inc.
9.41%
Lytton (Laurence W)
7.80%
Rock Springs Capital Management LP
7.70%
Nantahala Capital Management, LLC
7.49%
Other
48.09%
Shareholders
Shareholders
Proportion
CorMedix Inc
19.50%
Rosalind Advisors, Inc.
9.41%
Lytton (Laurence W)
7.80%
Rock Springs Capital Management LP
7.70%
Nantahala Capital Management, LLC
7.49%
Other
48.09%
Shareholder Types
Shareholders
Proportion
Hedge Fund
24.72%
Corporation
19.50%
Individual Investor
8.90%
Private Equity
6.47%
Investment Advisor/Hedge Fund
3.52%
Investment Advisor
3.30%
Research Firm
0.14%
Other
33.44%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
65
12.68M
31.11%
+4.13M
2025Q2
79
6.96M
33.93%
-506.98K
2025Q1
82
6.66M
34.60%
-832.94K
2024Q4
84
5.24M
30.79%
-2.31M
2024Q3
100
5.33M
31.39%
-2.35M
2024Q2
109
5.51M
32.40%
-2.29M
2024Q1
113
5.56M
32.76%
-881.00K
2023Q4
117
5.91M
35.12%
-445.19K
2023Q3
127
7.03M
43.10%
+3.84M
2023Q2
136
1.17M
10.69%
-920.00K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
CorMedix Inc
9.09M
19.94%
+9.09M
--
Sep 10, 2025
Rosalind Advisors, Inc.
2.00M
4.4%
--
--
Jun 30, 2025
Lytton (Laurence W)
3.64M
7.98%
+3.64M
--
Sep 10, 2025
Rock Springs Capital Management LP
3.59M
7.87%
+3.27M
+1034.17%
Sep 10, 2025
Nantahala Capital Management, LLC
1.99M
4.37%
--
--
Aug 29, 2025
Bleichroeder LP
426.62K
0.94%
--
--
Jun 30, 2025
Angotti Vincent J
368.15K
0.81%
+300.00
+0.08%
Aug 29, 2025
The Vanguard Group, Inc.
81.36K
0.18%
-156.17K
-65.75%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Oct 25, 2022
Merger
20→1
Oct 25, 2022
Merger
20→1
Oct 25, 2022
Merger
20→1
Oct 25, 2022
Merger
20→1
Date
Type
Ratio
Oct 25, 2022
Merger
20→1
Oct 25, 2022
Merger
20→1
Oct 25, 2022
Merger
20→1
Oct 25, 2022
Merger
20→1
FAQs
Who are the top five shareholders of Talphera Inc?
The top five shareholders of Talphera Inc are:
CorMedix Inc holds 9.09M shares, accounting for 19.94% of the total shares.
Rosalind Advisors, Inc. holds 2.00M shares, accounting for 4.40% of the total shares.
Lytton (Laurence W) holds 3.64M shares, accounting for 7.98% of the total shares.
Rock Springs Capital Management LP holds 3.59M shares, accounting for 7.87% of the total shares.
Nantahala Capital Management, LLC holds 1.99M shares, accounting for 4.37% of the total shares.
CorMedix Inc holds 9.09M shares, accounting for 19.94% of the total shares.
Rosalind Advisors, Inc. holds 2.00M shares, accounting for 4.40% of the total shares.
Lytton (Laurence W) holds 3.64M shares, accounting for 7.98% of the total shares.
Rock Springs Capital Management LP holds 3.59M shares, accounting for 7.87% of the total shares.
Nantahala Capital Management, LLC holds 1.99M shares, accounting for 4.37% of the total shares.
What are the top three shareholder types of Talphera Inc?
The top three shareholder types of Talphera Inc are:
CorMedix Inc
Rosalind Advisors, Inc.
Lytton (Laurence W)
CorMedix Inc
Rosalind Advisors, Inc.
Lytton (Laurence W)
How many institutions hold shares of Talphera Inc (TLPH)?
As of 2025Q3, 65 institutions hold shares of Talphera Inc, with a combined market value of approximately 12.68M, accounting for 31.11% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -2.82%.
What is the biggest source of revenue for Talphera Inc?
In FY2022, the DSUVIA business generated the highest revenue for Talphera Inc, amounting to 1.59M and accounting for 89.67% of total revenue.
